Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

New drug improve outcomes in metastatic breast cancer

by VHIO

2 years ago
Inavolisib, PIK3CA, metastatic breast cancer

Recently published in The New England Journal of Medicine1 results of a phase 3, double-blind, randomized trial show that the addition of inavolisib to the combination of palbociclib and fulvestrant l...

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

by Ysios Capital

1 year ago
lorundrostat, obstructive sleep apnea (OSA), hypertension, aldosterone

Obstructive sleep apnea represents Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases

ORYZON announces first patient dosed in NCI-sponsored iadademstat in combination with venetoclax and azacitidine clinical trial in first line acute myeloid leukemia

by Oryzon Genomics

1 year ago
iadademstat, venetoclax and azacitidine, acute myeloid leukemia (AML)

Oryzon Genomics announced today that the first patient has been dosed in a Phase I dose-finding clinical trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with venet...

CIC bioGUNE joins DIVAVACEHD project to develop a vaccine against Epizootic Hemorrhagic Disease (EHD) in cattle

by CIC bioGUNE

1 year ago
DIVAVACEHD, Epizootic Hemorrhagic Disease (EHD), CRISBio®

CIC bioGUNE is involved in DIVAVACEHD, a collaborative project aimed at developing an effective vaccine against Epizootic Hemorrhagic Disease (EHD) in cattle using CRISBio® technology.

Osteomyc evaluates OMO-103 in advanced osteosarcoma

by VHIO

1 year ago
advanced osteosarcoma, OMO-103, MYC

This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology (VHIO), part of the Vall d’Hebron Campus at Barcelona, through the spin-off P...

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

by Oryzon Genomics

1 year ago
iadademstat, myelodysplastic syndrome (MDS)

Oryzon Genomics, S.A. announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in c...

UE dostarlimab+chemotherapy approval endometrial cancer

by VHIO

1 year ago
endometrial cancer, dostarlimab+chemotherapy

The European Commission has approved dostarlimab in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary advanced or recurrent endometrial...

Eva González Suárez will advance towards the development of new inhibitors against breast cancer with a new grant from the European Research Council

by CNIO - Centro Nacional de Investigaciones Oncológicas

1 year ago
RANKL protein, triple negative breast cancer

González's team is working to develop new drugs, based on the inhibition of the RANKL protein, against triple-negative breast cancer

El Hospital público 12 de Octubre usa por primera vez el análisis genético de ARN para detectar qué tipo de pacientes con glioblastoma va a responder a un tratamiento

by Hospital Universitario 12 de Octubre

1 year ago
Azeliragon, glioblastoma, análisis genómico con ARN

El estudio servirá de base a dos ensayos internacionales para comprobar la eficacia del fármaco Azeliragon en estos tumores cerebrales agresivos

The different research projects at IQAC-CSIC for tumour treatment

by Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

1 year ago
MACTIDE-V, ReachGlio, glioblastomas, head and neck cancers, IQAC-CSIC

In the frame of World Cancer Day, held on 4th February, various research projects at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) stand out for their efforts to find new therapeutic s...

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

by Ysios Capital

1 year ago
Explore-CKD Phase 2, chronic kidney disease (CKD), Albuminuria, Hypertension

Mineralys Therapeutics today announced that it has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subject...

Discovering the molecular footprint of a drug: how an anticancer drug can become a solution against multiple viruses

by IrsiCaixa

1 year ago
plitidepsin

IrsiCaixa develops an innovative strategy to track the footprints left by drugs in cells, revealing how the anticancer drug plitidepsin modulates processes beyond its known mechanism of action